Genmab — December 2017

[Helge_LarsenPI-redaktør]

Graneman...Pandora har været hårdt angrebet af shortere.

[Bulder]

Så sc dara hjemme og Rev og dex er piller. Velcade findes også sc.

[E_L]

on this, i do not understand why the don't go to the 90min schedule that we saw in one abstract until SC is available?

[E_L]

there was an analyst question on this at the R&D day and it seemed as if Jan and Mateos where unaware of it, very strange

[Bulder]

some places they do already. Or split first infusion in two

[nohope]

Well, not necessary in the interest of all US hospitals to minimize cost.

[E_L]

ok. it is a HUGE difference already

[Bulder]

Were they unaware of the accellerated study?

[E_L]

it is not just cost; you can many more patients on the same day with the same number of chars and nurses

[Graneman]

@Helge, I know. Det har bla. været båret af en meget aggressiv og særdeles skiftende linje fra Lars Topholm og Carnegie, der har medvirket til at så tvivl om aktien. Men al den tvivl de har ført til markedet, har hidtil vist sig aldeles ubegrundet. Det er på kanten af det uetiske.

[E_L]

chairs

[E_L]

that is the sence i got Bulder, as far as i could hear the bad sound

[Graneman]

Nå - nok om Pandora og Vestas. Det her er jo en Genmab-chat. :9

[Bulder]

Will you ask him at Q&A?

[E_L]

maybe something for the Q&A

[E_L]

haha snap

[Bulder]

snap snap

[E_L]

i was actually just searching for that link from IMF video Durie and 2 others; may be worth posting again if you have it for those that havent seen yet

[E_L]

also on car-t

[E_L]

where PR mentioned how those trials had waiting lists for 1 year, and patients where carefully selected and vetted